Nasopharyngeal carcinoma (NPC) is a specific human malignancy with unique geographic distribution and genetic backgrounds. Although early treatment with radio-chemotherapy has been proven effective for NPC therapy, its therapeutic efficacy substantially diminishes in the late stages of this malignancy. In the tumor microenvironment of NPC, PD-L1 has been demonstrated as a critical factor in impairing T cell activation. As an etiological role for NPC development, it is found that Epstein-Barr virus (EBV) latent proteins upregulated PD-L1 expression. However, whether EBV lytic protein affects PD-L1 expression remains unclear. In this study, through monitoring the mRNA expression pattern of lytic genes and PD-L1 in EBV-positive NPC cell line NA, EBV immediately-early gene BRLF1(Rta) was found to have the potential for PD-L1 activation. Furthermore, we identified that Rta expression enhanced PD-L1 expression in mRNA and protein levels through quantitative real-time polymerase chain reaction and western blotting analysis. The luciferase reporter assay revealed that Rta expression enhanced PD-L1 promoter activity. We also demonstrated that Rta-induced PD-L1 expressions could impair interleukin 2 secretion of T cells, and this mechanism may be through ERK activation. These results displayed the importance of EBV Rta in PD-L1 expression in NPC and may give an alternative target for NPC therapy.
Get full access to this article
View all access options for this article.
References
1.
AdamsonAL, DarrD, Holley-GuthrieE, et al.Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol, 2000; 74(3):1224–1233.
2.
AnastasiadouE, StroopinskyD, AlimpertiS, et al.Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia, 2019; 33(1):132–147.
3.
AndersonNM, SimonMC. The tumor microenvironment. Curr Biol, 2020; 30(16):R921–R925.
4.
BiXW, WangH, ZhangWW, et al.PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol, 2016; 9(1):109.
5.
CarboneA, GloghiniA, Carlo-StellaC. Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?. Blood, 2018; 132(1):17–22.
6.
ChannappanavarR, TwardyBS, SuvasS. Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. PLoS One, 2012; 7(7):e39757.
7.
ChenYL, ChenYJ, TsaiWH, et al.The Epstein-Barr virus replication and transcription activator, Rta/BRLF1, induces cellular senescence in epithelial cells. Cell Cycle, 2009; 8(1):58–65.
8.
DarrCD, MauserA, KenneyS. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol, 2001; 75(13):6135–6142.
9.
FangW, ZhangJ, HongS, et al.EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget, 2014; 5(23):12189–12202.
10.
FathallahI, ParrocheP, GruffatH, et al.EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol, 2010; 185(11):6439–6447.
11.
FreemanGJ, LongAJ, IwaiY, et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 2000; 192(7):1027–1034.
12.
GranaiM, MundoL, AkarcaAU, et al.Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program. Infect Agent Cancer, 2020; 15:28.
13.
HildesheimA, LevinePH. Etiology of nasopharyngeal carcinoma: A review. Epidemiol Rev, 1993; 15(2):466–485.
14.
HislopAD, RessingME, van LeeuwenD, et al.A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med, 2007; 204(8):1863–1873.
15.
HoHH, IvashkivLB. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem, 2006; 281(20):14111–14118.
16.
HostKM, JacobsSR, WestJA, et al.Kaposi's sarcoma-associated herpesvirus increases PD-L1 and proinflammatory cytokine expression in human monocytes. mBio, 2017; 8(5):e00917-17.
17.
HsuMC, HsiaoJR, ChangKC, et al.Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol, 2010; 23(10):1393–1403.
18.
HuangSY, WuCC, ChengYJ, et al.Epstein-Barr virus BRLF1 induces genomic instability and progressive malignancy in nasopharyngeal carcinoma cells. Oncotarget, 2017a;8(45):78948–78964.
19.
HuangZY, XuP, LiJH, et al.Clinical significance of dynamics of programmed death ligand-1 expression on circulating CD14(+) monocytes and CD19(+) B cells with the progression of hepatitis B virus infection. Viral Immunol, 2017b;30(3):224–231.
20.
HuyeLE, NingS, KelliherM, et al.Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol Cell Biol, 2007; 27(8):2910–2918.
21.
JonesD, ComoCN, JingL, et al.Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. PLoS Pathog, 2019; 15(3):e1007650.
22.
LeeYH, ChiuYF, WangWH, et al.Activation of the ERK signal transduction pathway by Epstein-Barr virus immediate-early protein Rta. J Gen Virol, 2008; 89(Pt 10):2437–2446.
23.
LiX, ZhangW. Expression of PD-L1 in EBV-associated malignancies. Int Immunopharmacol, 2021; 95:107553.
24.
LinCT, WongCI, ChanWY, et al.Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest, 1990; 62(6):713–724.
25.
LongX, YangJ, ZhangX, et al.BRLF1 suppresses RNA Pol III-mediated RIG-I inflammasome activation in the early EBV lytic lifecycle. EMBO Rep, 2021; 22(1):e50714.
26.
LvJW, LiJY, LuoLN, et al.Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: Findings from recent advances in landmark trials. J Immunother Cancer, 2019; 7(1):159.
27.
McDermottAL, DuttSN, WatkinsonJC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci, 2001; 26(2):82–92.
28.
MiddeldorpJM, PegtelDM. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin Cancer Biol, 2008; 18(6):388–396.
29.
Morales-SanchezA, Fuentes-PananaEM. Epstein-Barr virus-associated gastric cancer and potential mechanisms of oncogenesis. Curr Cancer Drug Targets, 2017; 17(6):534–554.
30.
MuromotoR, IkedaO, OkabeK, et al.Epstein-Barr virus-derived EBNA2 regulates STAT3 activation. Biochem Biophys Res Commun, 2009; 378(3):439–443.
31.
ParkinDM, BrayF, FerlayJ, et al.Global cancer statistics, 2002. CA Cancer J Clin, 2005; 55(2):74–108.
32.
RessingME, van LeeuwenD, VerreckFA, et al.Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol, 2005; 79(2):841–852.
33.
RickinsonAB, KieffE. Epstein-Barr virus. In: Field's Virology. (Knipe DM, Howley PM, eds.) Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2001; pp. 2575–2627.
34.
RoweM, GlaunsingerB, van LeeuwenD, et al.Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A, 2007; 104(9):3366–3371.
35.
SchonrichG, RafteryMJ. The PD-1/PD-L1 axis and virus infections: A delicate balance. Front Cell Infect Microbiol, 2019; 9:207.
36.
ShahKM, StewartSE, WeiW, et al.The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene, 2009; 28(44):3903–3914.
37.
SunC, MezzadraR, SchumacherTN. Regulation and function of the PD-L1 checkpoint. Immunity, 2018; 48(3):434–452.
38.
TuZ, PierceRH, KurtisJ, et al.Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology, 2010; 138(1):305–314.
39.
WotmanM, HermanSW, CostantinoP, et al.The prognostic role of programmed death-ligand 1 in nasopharyngeal carcinoma. Laryngoscope, 2020; 130(11):2598–2606.
40.
WuCC, FangCY, HsuHY, et al.Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes. Antiviral Res, 2016a;132:99–110.
41.
WuCC, FangCY, HsuHY, et al.EBV reactivation as a target of luteolin to repress NPC tumorigenesis. Oncotarget, 2016b;7:18999–19017.
42.
WuCC, LeeTY, ChengYJ, et al.The dietary flavonol kaempferol inhibits Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells. Molecules, 2022; 27(23):8158.
43.
YanagiY, HaraY, MabuchiS, et al.PD-L1 upregulation by lytic induction of Epstein-Barr virus. Virology, 2022; 568:31–40.
44.
YipYL, LinW, DengW, et al.Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epstein-Barr virus reactivation. Lab Invest, 2018; 98(8):1093–1104.
45.
YoungLS, RickinsonAB. Epstein-Barr virus: 40 years on. Nat Rev, 2004; 4(10):757–768.
46.
ZuoJ, CurrinA, GriffinBD, et al.The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog, 2009; 5(1):e1000255.
47.
ZuoJ, ThomasWA, HaighTA, et al.Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. PLoS Pathog, 2011; 7(12):e1002455.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
